| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $90,885,729 ) (Continued on the next page) |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA246659 | An INteractive Survivorship Program to Improve Healthcare REsources [INSPIRE] for Adolescent and Young Adult (AYA) Cancer Survivors | 002 | 4 | NIH | 3/13/2025 | $505,874 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35HL171556 | Promoting T cell reconstitution after hematopoietic cell transplantation | 000 | 2 | NIH | 12/10/2024 | $1,075,992 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 003 | 3 | NIH | 1/15/2025 | $163,398 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 003 | 3 | NIH | 1/15/2025 | -$163,398 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 002 | 3 | NIH | 12/12/2024 | $163,398 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 001 | 3 | NIH | 12/6/2024 | $1,415,922 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA252050 | Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer | 001 | 5 | NIH | 3/12/2025 | $420,640 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 001 | 20 | NIH | 11/21/2024 | $3,656,634 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 001 | 20 | NIH | 11/21/2024 | $732,039 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 001 | 20 | NIH | 11/21/2024 | $5,399,174 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 001 | 20 | NIH | 11/21/2024 | $636,816 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI054423 | Genetic requirements of Helicobacter pylori infection | 000 | 21 | NIH | 1/22/2025 | $489,160 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA233328 | Hutchinson Center as Lead Academic Participating Site (UG1) | 000 | 6 | NIH | 3/10/2025 | $297,348 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL148189 | Extrinsic regulation of primitive, myeloid-biased hematopoietic stem cells by Semaphorin 4a | 000 | 6 | NIH | 12/16/2024 | $448,040 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA276308 | Transcriptional-translational conflict in bladder epithelial homeostasis and cancer | 000 | 3 | NIH | 11/22/2024 | $512,155 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | K99GM152821 | Visualizing transcription factor binding and chromatin assembly on newly synthesized DNA | 000 | 2 | NIH | 12/3/2024 | $125,000 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R21CA286216 | Targeting alloantigen presentation in bone marrow to enhance graft-versus-leukemia effects | 000 | 2 | NIH | 12/19/2024 | $185,131 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA287573 | Interrogating roles for REST in small cell lung cancer therapy response and resistance | 000 | 2 | NIH | 11/6/2024 | $523,869 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA262556 | Expanding the cancer paralog genetic interaction map to enable precision oncology | 000 | 2 | NIH | 2/12/2025 | $493,706 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 000 | 20 | NIH | 11/7/2024 | $141,120 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 000 | 20 | NIH | 11/7/2024 | $699,159 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI183406 | Deep Learning-based Protein Design of HIV-1 Env GP120 Core Immunogens for CD4 Binding Site Germline Targeting | 000 | 2 | NIH | 1/15/2025 | $772,776 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R21AI178255 | Viral gene drive as a novel curative therapy for HSV infection | 000 | 2 | NIH | 12/13/2024 | $247,126 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA286450 | Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy | 000 | 2 | NIH | 1/24/2025 | $601,262 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL161037 | Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Cell Transplant Recipients | 000 | 5 | NIH | 11/22/2024 | $668,582 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | K23AI163343 | Cytomegalovirus-specific Immune Reconstitution after Hematopoietic Cell Transplantation in the Era of Modern Antiviral Prophylaxis | 000 | 5 | NIH | 1/22/2025 | $189,432 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA240832 | Novel Approaches to CD33-Directed Radioimmunotherapy | 000 | 7 | NIH | 12/23/2024 | $595,700 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA287013 | Statistics and Data Management Center (SDMC) for the NCI Cancer Screening Research Network (CSRN) | 000 | 2 | NIH | 1/1/2025 | $1,313,116 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA286954 | NCI Cancer Screening Research Network: Coordinating and Communication Center | 000 | 2 | NIH | 12/17/2024 | $1,354,656 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA234488 | Role of tumor cell cluster-induced signaling in breast cancer metastasis | 000 | 7 | NIH | 12/20/2024 | $362,340 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AR045203 | D4Z4 Coding Transcripts and FSHD | 000 | 26 | NIH | 12/18/2024 | $514,273 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM140823 | Mechanisms of transcriptional regulation and transcription factor specificity | 001 | 5 | NIH | 2/20/2025 | $1,009,413 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 5 | NIH | 11/25/2024 | $125,000 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 5 | NIH | 11/25/2024 | $605,441 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI176563 | Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization | 000 | 3 | NIH | 1/21/2025 | $780,080 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32GM153148 | Investigating the chromatin landscape of complex tissues through cell-type-specific patterns | 000 | 2 | NIH | 12/23/2024 | $74,284 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32HD113384 | Developmental mechanisms specifying vagal innervation of organ targets | 000 | 2 | NIH | 12/9/2024 | $76,756 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL148565 | Clonal Hematopoiesis in the Women's Health Initiative | 002 | 7 | NIH | 3/10/2025 | $654,437 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA285227 | Rational Vaccine Design to prevent HIV-Associated Lymphoma | 000 | 2 | NIH | 3/4/2025 | $647,437 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI175535 | Defining Protective CMV Immunity after Transplantation | 000 | 3 | NIH | 1/23/2025 | $750,866 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI173199 | Breastmilk antibodies regulate neonatal immunity to the microbiota | 000 | 3 | NIH | 1/22/2025 | $624,131 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA277133 | Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies | 000 | 3 | NIH | 11/15/2024 | $361,548 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01NS119650 | Defining cellular states of quiescence in human brain tumors | 000 | 6 | NIH | 12/17/2024 | $463,899 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA249528 | Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance | 000 | 6 | NIH | 1/2/2025 | $362,340 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI177095 | Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunization | 001 | 2 | NIH | 2/28/2025 | $873,050 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 000 | 20 | NIH | 11/21/2024 | $392,157 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI171186 | Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses | 000 | 3 | NIH | 2/14/2025 | $708,446 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI165821 | Forecasting influenza evolution on a heterogeneous immune landscape | 000 | 4 | NIH | 1/23/2025 | $744,369 |
| | 2025 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI170214 | Developing Durable, Env-Boosted CAR T Cells for HIV Cure | 000 | 3 | NIH | 10/31/2024 | $814,373 |
|
